Halo™ 275: the First Commercially Available Visible-light OCT System for Small Animal Research

JANUARY 18, 2020

Opticent Health announces the intended launch of its newest commercial system, Halo 275. First shipments are expected in Summer 2021. With unmatched axial resolution, unique functional imaging capabilities and tremendous flexibility for a range of applications, Halo 275 is the most powerful small animal research optical coherence tomography (OCT) system to date. It is uniquely positioned to help users discover more about the eye than ever before.

 

Halo 275 is the first commercially available visible-light OCT (vis-OCT) system. Optimized for research in common model organisms such as mice and rats, Halo 275 harnesses the power of vis-OCT, a cutting-edge imaging modality first pioneered by Prof. Hao F. Zhang of Northwestern University. Achieving the highest axial resolution (up to 1.3 um) of any research system, Halo 275 empowers researchers to visualize numerous tissue structures unable to be resolved by other systems. Additionally, vis-OCT drives novel functional imaging capabilities, including accurate oxygen measurements in large vessels and ultrastructural analysis of various anatomical features, ranging from the ganglion layer to Schlemm’s canal.

 

“Ophthalmology researchers have been waiting for OCT systems that offer more flexibility and better performance for a variety of research topics,” shared Kieren Patel, CEO of Opticent Health. “Halo 275 serves our customers’ needs more effectively by delivering a flexible multi-modal platform that helps tackle a variety of research questions spanning basic investigation of disease etiology to translational applications such as drug screening and mechanism of action.”

 

“Opticent Health’s Halo instrument has become a fantastic addition to my lab in helping investigate fundamental questions concerning eye development and disease,” said Prof. Xiaorong Liu, Associate Professor of Biology and Psychology at the University of Virginia and Opticent Health early access user. “The range of add-on modules including use of both vis-OCT and fluorescence in one platform opens up new possibilities for our research.” 

 

Halo 275 offers tremendous flexibility in ophthalmology research, supporting an extensive range of applications in both the anterior and posterior segments of the eye.  Further, users can purchase additional imaging models to combine both OCT and fluorescence imaging which helps researchers take advantage of genetically engineered reporter assays in mice. Halo 275 is offered as a fully integrated system, including animal holders, imaging system,s and software to enable both novice and expert users.

 

Shipment of Halo 275 is expected in Summer 2021. To learn more, please check back for periodic product updates and data set releases or contact orders@opticenthealth.com

For Research Use Only.  Not for use in diagnostic procedures.